^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MET fusion

    i
    Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
    Entrez ID:
    4233
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    9ms
    A report on MET fusions in NSCLC published @JTOonline by Dr. Jurgen Wolf & colleagues Prevalence approximately 0.29% Five different fusion partners identified and responses seen with MET TKI Tx Emerging biomarker in NSCLC and beyond! https://t.co/TB4rGReynn (@chulkimMD)
    MET fusion
    over1year
    Case report @ClinicalLung showing a novel PRKAR1A:MET fusion in NSCLC with a dramatic response to crizotinib. #MET fusions are rare with multiple different fusion partners described and they may not all be equally actionable. More work needed here. https://t.co/WpZM1Cp17h (@StephenVLiu)
    Clinical
    |
    PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha)
    |
    MET fusion
    |
    Xalkori (crizotinib)
    almost3years
    Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib @JTOonline https://t.co/ZCmqRnarbu (@VivekSubbiah)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • KIF5B (Kinesin Family Member 5B)
    |
    MET amplification • MET D1228N • MET fusion
    |
    Retevmo (selpercatinib) • Tabrecta (capmatinib)
    almost3years
    ⭐️Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib @JTOonline @oncoOuLungCA https://t.co/PoShj6K8vu (@VivekSubbiah)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • KIF5B (Kinesin Family Member 5B)
    |
    MET amplification • MET D1228N • MET fusion
    |
    Retevmo (selpercatinib) • Tabrecta (capmatinib)
    3years
    Tepotinib Efficacy in a Patient with Non‐Small Cell Lung Cancer with Brain Metastasis Harboring an HLA‐DRB1‐MET Gene Fusion https://t.co/YF1ezdaCDP (@AndresFCardonaZ)
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    MET fusion
    |
    Tepmetko (tepotinib)